553 related articles for article (PubMed ID: 24471292)
1. [Role of anti-TNF therapy (biologics) in the treatment of chronic inflammatory bowel disease in children].
Kolacek S
Acta Med Croatica; 2013 Apr; 67(2):89-92. PubMed ID: 24471292
[TBL] [Abstract][Full Text] [Related]
2. A Review on the Use of Anti-TNF in Children and Adolescents with Inflammatory Bowel Disease.
Aardoom MA; Veereman G; de Ridder L
Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31126015
[TBL] [Abstract][Full Text] [Related]
3. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
Magro F; Portela F
BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
[TBL] [Abstract][Full Text] [Related]
4. The association of psoriasiform rash with anti-tumor necrosis factor (anti-TNF) therapy in inflammatory bowel disease: a single academic center case series.
Afzali A; Wheat CL; Hu JK; Olerud JE; Lee SD
J Crohns Colitis; 2014 Jun; 8(6):480-8. PubMed ID: 24268978
[TBL] [Abstract][Full Text] [Related]
5. Trough s-infliximab and antibodies towards infliximab in a cohort of 79 IBD patients with maintenance infliximab treatment.
Marits P; Landucci L; Sundin U; Davidsdottir L; Nilsson J; Befrits R; Wikström AC; Eberhardson M
J Crohns Colitis; 2014 Aug; 8(8):881-9. PubMed ID: 24486178
[TBL] [Abstract][Full Text] [Related]
6. Anti-TNF therapy in inflammatory bowel diseases: a huge review.
Peyrin-Biroulet L
Minerva Gastroenterol Dietol; 2010 Jun; 56(2):233-43. PubMed ID: 20485259
[TBL] [Abstract][Full Text] [Related]
7. Achievement of deep remission during scheduled maintenance therapy with TNFα-blocking agents in IBD.
Molander P; Sipponen T; Kemppainen H; Jussila A; Blomster T; Koskela R; Nissinen M; Rautiainen H; Kuisma J; Kolho KL; Färkkilä M
J Crohns Colitis; 2013 Oct; 7(9):730-5. PubMed ID: 23182163
[TBL] [Abstract][Full Text] [Related]
8. [TNF-alpha blocking therapy in chronic inflammatory bowel disease].
Molnár T
Orv Hetil; 2009 Sep; 150(38):1773-9. PubMed ID: 19740722
[TBL] [Abstract][Full Text] [Related]
9. Tumour necrosis factor (TNF) antagonist therapy for paediatric inflammatory bowel disease: A systematic review.
Martín-García P; Alonso-Arroyo A; Catalá-López F
Med Clin (Barc); 2023 Jun; 160(11):501-516. PubMed ID: 36967304
[TBL] [Abstract][Full Text] [Related]
10. Anti-TNF-alpha treatment strategies: results and clinical perspectives.
D'Haens G
Gastroenterol Clin Biol; 2009 Jun; 33 Suppl 3():S209-16. PubMed ID: 20117344
[TBL] [Abstract][Full Text] [Related]
11. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D
Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
[TBL] [Abstract][Full Text] [Related]
12. The Italian Society of Gastroenterology (SIGE) and the Italian Group for the study of Inflammatory Bowel Disease (IG-IBD) Clinical Practice Guidelines: The use of tumor necrosis factor-alpha antagonist therapy in inflammatory bowel disease.
Orlando A; Armuzzi A; Papi C; Annese V; Ardizzone S; Biancone L; Bortoli A; Castiglione F; D'Incà R; Gionchetti P; Kohn A; Poggioli G; Rizzello F; Vecchi M; Cottone M; ;
Dig Liver Dis; 2011 Jan; 43(1):1-20. PubMed ID: 20843756
[TBL] [Abstract][Full Text] [Related]
13. Concomitant therapy with methotrexate and anti-TNF-α in pediatric patients with refractory crohn's colitis: a case series.
Absah I; Faubion WA
Inflamm Bowel Dis; 2012 Aug; 18(8):1488-92. PubMed ID: 21882301
[TBL] [Abstract][Full Text] [Related]
14. European Crohn's and Colitis Organisation Topical Review on Treatment Withdrawal ['Exit Strategies'] in Inflammatory Bowel Disease.
Doherty G; Katsanos KH; Burisch J; Allez M; Papamichael K; Stallmach A; Mao R; Berset IP; Gisbert JP; Sebastian S; Kierkus J; Lopetuso L; Szymanska E; Louis E
J Crohns Colitis; 2018 Jan; 12(1):17-31. PubMed ID: 28981623
[TBL] [Abstract][Full Text] [Related]
15. [Biologics in current therapy for inflammatory bowel disease].
Hisamatsu T; Hibi T
Nihon Rinsho Meneki Gakkai Kaishi; 2009 Jun; 32(3):168-79. PubMed ID: 19564713
[TBL] [Abstract][Full Text] [Related]
16. Psoriasis and Psoriasiform Eruptions in Pediatric Patients with Inflammatory Bowel Disease Treated with Anti-Tumor Necrosis Factor Alpha Agents.
Eickstaedt JB; Killpack L; Tung J; Davis D; Hand JL; Tollefson MM
Pediatr Dermatol; 2017 May; 34(3):253-260. PubMed ID: 28211161
[TBL] [Abstract][Full Text] [Related]
17. New concepts in anti-tumor necrosis factor therapy for inflammatory bowel disease.
Sandborn WJ
Rev Gastroenterol Disord; 2005; 5(1):10-8. PubMed ID: 15741928
[TBL] [Abstract][Full Text] [Related]
18. Use of Anti-TNFα Agents and Time to First-time Surgery in Paediatric Patients with Ulcerative Colitis and Crohn's Disease.
Larsen MD; Qvist N; Nielsen J; Kjeldsen J; Nielsen RG; Nørgård BM
J Crohns Colitis; 2016 Jun; 10(6):650-6. PubMed ID: 26802081
[TBL] [Abstract][Full Text] [Related]
19. [Infliximab therapy for Crohn's disease - a practical guideline: actualised consensus of the working group for chronic inflammatory bowel diseases of the Austrian Society for Gastroenterology and Hepatology].
Reinisch W; Dejaco C; Feichtenschlager T; Haas T; Kaser A; Miehsler W; Novacek G; Petritsch W; Platzer R; Tilg H; Vogelsang H; Knoflach P;
Z Gastroenterol; 2011 Apr; 49(4):534-42. PubMed ID: 21442574
[TBL] [Abstract][Full Text] [Related]
20. New strategies in the management of inflammatory bowel disease.
Rutgeerts P; Baert F
Acta Clin Belg; 1999 Oct; 54(5):274-80. PubMed ID: 10555385
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
